Cover Image
市場調查報告書

Suda Ltd的產品平台分析

Suda Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321956
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Suda Ltd的產品平台分析 Suda Ltd - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 30 Pages
簡介

Suda Ltd是總公司設立於澳洲的藥物遞輸企業,擁有治療嚴重的兒童瘧疾用舌下噴霧,及用於治療成人急性偏頭痛的口腔噴霧等產品。

本報告提供Suda Ltd 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Suda Ltd 基本資料

  • Suda Ltd 概要
  • 主要資訊
  • 企業資料

Suda Ltd :R&D概要

  • 主要的治療範圍

Suda Ltd :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Suda Ltd :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Suda Ltd :藥物簡介

  • sumatriptan succinate
  • sildenafil citrate
  • midazolam hydrochloride
  • ondansetron hydrochloride
  • SUD-004

Suda Ltd :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Suda Ltd :最新的開發平台資訊

Suda Ltd :開發暫停中的計劃

Suda Ltd :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • ondansetron hydrochloride
    • ropinirole hydrochloride

Suda Ltd :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07719CDB

Summary

Global Markets Direct's, 'Suda Ltd - Product Pipeline Review - 2015', provides an overview of the Suda Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Suda Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Suda Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Suda Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Suda Ltd's pipeline products

Reasons to buy

  • Evaluate Suda Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Suda Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Suda Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Suda Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Suda Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Suda Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Suda Ltd Snapshot
    • Suda Ltd Overview
    • Key Information
    • Key Facts
  • Suda Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Suda Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Suda Ltd - Pipeline Products Glance
    • Suda Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Suda Ltd - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Suda Ltd - Drug Profiles
    • sumatriptan succinate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SUD-003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SUD-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • midazolam hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ondansetron hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Suda Ltd - Pipeline Analysis
    • Suda Ltd - Pipeline Products by Target
    • Suda Ltd - Pipeline Products by Route of Administration
    • Suda Ltd - Pipeline Products by Molecule Type
    • Suda Ltd - Pipeline Products by Mechanism of Action
  • Suda Ltd - Recent Pipeline Updates
  • Suda Ltd - Dormant Projects
  • Suda Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ondansetron hydrochloride
      • ropinirole hydrochloride
  • Suda Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Suda Ltd, Key Information
  • Suda Ltd, Key Facts
  • Suda Ltd - Pipeline by Indication, 2015
  • Suda Ltd - Pipeline by Stage of Development, 2015
  • Suda Ltd - Monotherapy Products in Pipeline, 2015
  • Suda Ltd - Phase II, 2015
  • Suda Ltd - Phase I, 2015
  • Suda Ltd - Unknown, 2015
  • Suda Ltd - Pipeline by Target, 2015
  • Suda Ltd - Pipeline by Route of Administration, 2015
  • Suda Ltd - Pipeline by Molecule Type, 2015
  • Suda Ltd - Pipeline Products by Mechanism of Action, 2015
  • Suda Ltd - Recent Pipeline Updates, 2015
  • Suda Ltd - Dormant Developmental Projects,2015
  • Suda Ltd - Discontinued Pipeline Products, 2015

List of Figures

  • Suda Ltd - Pipeline by Top 10 Indication, 2015
  • Suda Ltd - Pipeline by Stage of Development, 2015
  • Suda Ltd - Monotherapy Products in Pipeline, 2015
  • Suda Ltd - Pipeline by Top 10 Target, 2015
  • Suda Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Suda Ltd - Pipeline by Top 10 Molecule Type, 2015
  • Suda Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top